Thisshould include a careful assessment of treatment impact on patient quality of life.One study conducted by Kreuz and colleagues[89] demonstrated that patients with severe HAE who discontinuedlong-term prophylaxis with danazol because of lack of efficacy, intolerability, orsevere side effects had a significant improvement in quality-of-life scores afterreceiving C1-esterase-inhibitor therapy (Figure 4)[89]. Here, C1S is linked to hereditary angioedema.